Brief: Spago Nanomedical Q2 Sales SEK 81 Thousand
Aug 20 (Reuters) - Spago Nanomedical Q2 operating expenses SEK -8.291 million. Q2 adjusted EPS SEK -0.02 Q2 net income SEK -6.964 million
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose